Sensei Biotherapeutics (NASDAQ:FTH) Trading 7.4% Higher – What’s Next?

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH) traded up 7.4% during mid-day trading on Thursday . The company traded as high as $38.41 and last traded at $38.7930. Approximately 40,523 shares changed hands during mid-day trading, a decline of 81% from the average daily volume of 214,469 shares. The stock had previously closed at $36.12.

Wall Street Analyst Weigh In

FTH has been the subject of several recent research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Sensei Biotherapeutics in a research report on Thursday, June 4th. Oppenheimer assumed coverage on Sensei Biotherapeutics in a research report on Tuesday, July 28th. They issued an “outperform” rating and a $60.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Sensei Biotherapeutics in a research note on Tuesday, August 11th. Wall Street Zen upgraded Sensei Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Finally, Loop Capital set a $50.00 target price on Sensei Biotherapeutics in a research note on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Sensei Biotherapeutics currently has an average rating of “Moderate Buy” and an average price target of $55.00.

Sensei Biotherapeutics Trading Up 4.2%

The business has a 50 day simple moving average of $30.73. The firm has a market capitalization of $973.01 million, a price-to-earnings ratio of -0.26 and a beta of -0.28.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($5.04) by $2.20. As a group, equities research analysts expect that Sensei Biotherapeutics, Inc. will post -13.18 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Anand Kiran Parikh bought 2,806 shares of the company’s stock in a transaction on Monday, June 22nd. The shares were purchased at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the acquisition, the chief executive officer owned 764,234 shares of the company’s stock, valued at approximately $15,101,263.84. This represents a 0.37% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Brian C. Stephenson purchased 9,391 shares of the business’s stock in a transaction on Wednesday, June 24th. The stock was bought at an average cost of $26.13 per share, for a total transaction of $245,386.83. Following the purchase, the chief financial officer owned 26,804 shares of the company’s stock, valued at approximately $700,388.52. This represents a 53.93% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 49,494 shares of company stock worth $1,188,822 in the last quarter. 7.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sensei Biotherapeutics

Large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC lifted its position in Sensei Biotherapeutics by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock valued at $123,000 after acquiring an additional 1,100 shares in the last quarter. Citadel Advisors LLC bought a new stake in shares of Sensei Biotherapeutics in the second quarter valued at about $307,000. Bank of America Corp DE lifted its holdings in shares of Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares in the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Sensei Biotherapeutics during the second quarter worth about $3,610,000. Finally, Stempoint Capital LP acquired a new position in shares of Sensei Biotherapeutics during the first quarter worth about $4,188,000. Institutional investors own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.